The “c” in cGMP is the part most teams overlook
Current Good Manufacturing Practice is the full expansion of cGMP. The regulations — codified in 21 CFR Parts 210 and 211 for finished pharmaceuticals and Part 4 for combination products — define the minimum requirements for the methods, facilities, and controls used in manufacturing, processing, and packing pharmaceutical products. They are enforced by the FDA in the United States and serve as the baseline quality framework that every pharmaceutical manufacturer operating in the US market must meet.
The “current” modifier is not decorative. It means compliance is measured against contemporary standards and available technology, not against the standards that existed when the regulation was written. A manufacturer that uses 1990s environmental monitoring practices when real-time continuous monitoring is commercially available and widely adopted may be found non-compliant — even if the older practices met the regulatory expectations of 1990. This is the lever that quietly pulls AI, computer vision, and predictive monitoring into the cGMP conversation over time.
What does cGMP actually require?
| Domain | Requirement | Reference |
|---|---|---|
| Personnel | Qualified, trained, adequate in number | 21 CFR 211.25 |
| Buildings and facilities | Suitable design, adequate space, defined cleaning procedures | 21 CFR 211.42–58 |
| Equipment | Appropriate design, adequate size, calibrated and maintained | 21 CFR 211.63–72 |
| Production and process controls | Written procedures, in-process testing, yield calculations | 21 CFR 211.100–115 |
| Laboratory controls | Testing and approval/rejection of components, products, packaging | 21 CFR 211.160–176 |
| Records and reports | Batch records, distribution records, complaint files | 21 CFR 211.180–198 |
Manufacturing operations must document, control, and trace every activity from raw material intake to final release. Batch records must be complete, legible, and attributable to specific personnel. Deviations from established procedures must be investigated, documented, and resolved before product is released. None of this is optional, and none of it is satisfied by software dashboards that look tidy but lack an enforceable audit trail.
How cGMP differs from GMP
GMP and cGMP differ mainly in jurisdiction and the time period they reflect. GMP (without the “c”) typically refers to the WHO or EU frameworks for good manufacturing practice. cGMP is the FDA-specific term that emphasises the evolutionary nature of the standard.
In practical terms, both frameworks require the same core elements: validated processes, controlled environments, qualified personnel, documented procedures, and quality oversight. The differences sit in the details — specific documentation requirements, inspection frequency, enforcement mechanisms, and regulatory expectations for adopting new technology.
EU GMP (governed by EudraLex Volume 4) and US cGMP (21 CFR Parts 210/211) are largely harmonised through ICH Q7 and Q10 guidelines, but differences remain in areas like Annex 11 requirements for computerised systems and the FDA’s CSA approach to software validation. Manufacturers serving both markets must meet the more stringent requirement in each area — which varies by topic. The regulatory framework for computerised systems under EU GMP carries specific requirements for data integrity, audit trails, and electronic signatures that sit alongside cGMP’s documentation obligations.
Why does the word “current” matter for AI adoption?
AI adoption in pharmaceutical manufacturing is shaped by the “current” modifier in cGMP. If AI-based process monitoring, computer vision inspection, or predictive maintenance becomes the industry standard for a given application, manufacturers that continue using manual methods may eventually face questions about whether their approach still meets the “current” expectation.
This does not mean regulators require AI adoption today. It means that as AI systems demonstrate reliability and become commercially established in pharmaceutical manufacturing, the definition of “current” good practice will widen to encompass them. Manufacturers that adopt AI early do so for operational advantage. Manufacturers that delay eventually face a different question: whether their practices still qualify as current.
In our experience, the better way to think about this is not “AI is mandatory yet” but “the regulatory definition of acceptable practice is not frozen”. We see this pattern regularly in environmental monitoring, visual inspection, and deviation triage — the technology bar rises every few years, and cGMP rises with it because the word “current” is doing structural work in the regulation.
How does cGMP apply to AI-based quality decisions?
AI systems that make or inform quality decisions—material acceptance, in-process monitoring, or product release—become regulated cGMP tools. This triggers specific requirements: validation, change control, user training, and periodic performance review. The line that matters is not “does AI touch the process” but “does AI influence a quality decision”. A vision model that screens packaging photos for an operator’s review is in scope; a model that helps a maintenance team schedule a non-GxP HVAC service is not. The boundary between GxP and non-GxP usage is exactly what our GxP compliance for AI software in pharma manufacturing explainer maps out in detail.
Validation of AI-based quality decision systems follows the principles of analytical method validation: demonstrate accuracy (does the AI make correct decisions?), precision (does it make consistent decisions?), robustness (does it perform consistently under varying conditions?), and specificity (does it distinguish between accept and reject conditions without ambiguity?). The frameworks pharma teams already use for HPLC method validation translate surprisingly well — the same four characteristics, applied to a model rather than a chromatogram.
The validation challenge specific to AI is model drift: a model’s performance may degrade over time as the manufacturing process or product characteristics change subtly. cGMP requires that quality-critical measurements are periodically verified. For AI systems, this means ongoing performance monitoring against a reference standard — typically confirmed-correct decisions from expert human reviewers. Common stacks for this work include ONNX or TensorRT for the runtime, PyTorch for retraining cycles, and MLflow for run tracking and lineage, but the technical choice is downstream of the governance question.
We treat performance monitoring as a feedback loop. An observed range we use as a planning heuristic across our pharma engagements (not a benchmarked rate) is that 1–5% of AI decisions are reviewed by quality personnel as a sampled audit, with the agreement rate between AI and human decisions tracked monthly. If agreement drops below the validated threshold (often set at 95%), an investigation is triggered and the model may require retraining and revalidation. This ongoing review satisfies cGMP’s expectation that quality-critical systems are periodically reassessed rather than validated once and forgotten. We apply that same periodic-reassessment habit across the rest of our life-sciences AI practice.
